Mild Cognitive Impairment News - LARVOL Sigma

Mild Cognitive Impairment

Welcome, Profile Billing Logout

9 Mechanisms of Action

«1 2 3 4 5 678 »

||||||||||  davunetide intranasal (AL-108) / Endo
Enrollment change:  Safety, Tolerability and Efficacy Study to Evaluate Subjects With Mild Cognitive Impairment (clinicaltrials.gov) -  Oct 9, 2012
P2, N=144, Completed,  Sponsor: Allon Therapeutics
N=120 --> 144

||||||||||  pioglitazone / Generic mfg.
Enrollment closed:  POEM: Pioglitazone Or Exercise to Treat Mild Cognitive Impairment (MCI) (clinicaltrials.gov) -  Oct 2, 2012
P2, N=300, Active, not recruiting,  Sponsor: University of Colorado, Denver
N=120 --> 144 Recruiting --> Active, not recruiting

|||||||||| Trial completion: e-CHAMP: Enhancing Care for Hospitalized Older Adults With Memory Problems (clinicaltrials.gov) - Sep 19, 2012
P=N/A, N=424, Completed, Sponsor: Regenstrief Institute, IU Center for Aging Research
Recruiting --> Active, not recruiting Active, not recruiting --> Completed

|||||||||| New P3 trial: Efficacy of Ubiquitous SR-based Memory Advancement and Rehabilitation Training (U-SMART) (clinicaltrials.gov) - Sep 17, 2012
P3, N=50, Recruiting, Sponsor: Seoul National University Bundang Hospital

|||||||||| Enrollment change: Enhancing Care Coordination: Hospital to Home for Cognitively Impaired Older Adults and Their Caregivers (clinicaltrials.gov) - Sep 11, 2012
P=N/A, N=814, Completed, Sponsor: University of Pennsylvania
Active, not recruiting --> Completed N=420 --> 814

|||||||||| Trial completion: SNIFF 120: Study of Nasal Insulin to Fight Forgetfulness (120 Days) (clinicaltrials.gov) - Sep 11, 2012
P2, N=173, Completed, Sponsor: University of Washington
N=420 --> 814 Active, not recruiting --> Completed

|||||||||| Trial completion: Enhancing Care Coordination: Hospital to Home for Cognitively Impaired Older Adults and Their Caregivers (clinicaltrials.gov) - Sep 11, 2012
P=N/A, N=814, Completed, Sponsor: University of Pennsylvania
Active, not recruiting --> Completed Active, not recruiting --> Completed

||||||||||  levetiracetam / Generic mfg.
Trial completion:  Levetiracetam and Memory Function in Amnestic Mild Cognitive Impairment (MCI) (clinicaltrials.gov) -  Aug 29, 2012
P2, N=144, Completed,  Sponsor: Johns Hopkins University
Active, not recruiting --> Completed Recruiting --> Completed

||||||||||  HPP854 / vTv Therapeutics
Trial termination:  Safety Study of HPP854 in Subjects With Mild Cognitive Impairment or a Diagnosis of Mild Alzheimer's Disease (clinicaltrials.gov) -  Aug 28, 2012
P1, N=7, Terminated,  Sponsor: High Point Pharmaceuticals, LLC.
Recruiting --> Completed Recruiting --> Terminated

||||||||||  HPP854 / vTv Therapeutics
Enrollment change:  Safety Study of HPP854 in Subjects With Mild Cognitive Impairment or a Diagnosis of Mild Alzheimer's Disease (clinicaltrials.gov) -  Aug 28, 2012
P1, N=7, Terminated,  Sponsor: High Point Pharmaceuticals, LLC.
Recruiting --> Terminated N=30 --> 7

||||||||||  TTP4000 / vTv Therapeutics
Enrollment closed:  A Safety Study of TTP4000 in Subjects With Alzheimer's Disease (clinicaltrials.gov) -  Aug 28, 2012
P1, N=16, Active, not recruiting,  Sponsor: TransTech Pharma
N=30 --> 7 Recruiting --> Active, not recruiting

|||||||||| New P3 trial: Effectiveness of an Electronic Training Program for Orienting and Interpreting [18F]Flutemetamol Positron Emission Tomography (PET) Images (clinicaltrials.gov) - Aug 23, 2012
P3, N=276, Completed, Sponsor: GE Healthcare

|||||||||| New P2/3 trial: A Phase II Trial of Florbetapir (18F) Positron Emission Tomography (PET) Imaging in Japan of Healthy Volunteers, Patients With Mild Cognitive Impairment (MCI) and Patients With Alzheimer's Disease (AD) (clinicaltrials.gov) - Aug 9, 2012
P2/3, N=48, Completed, Sponsor: Avid Radiopharmaceuticals

|||||||||| New P1 trial: 3ECog: Effectiveness of a Brain-Computer Interface Based System for Cognitive Enhancement in the Normal Elderly (clinicaltrials.gov) - Aug 8, 2012
P1, N=40, Recruiting, Sponsor: Duke-NUS Graduate Medical School

|||||||||| Enrollment open: Measuring the Impact of Cognitive and Psychosocial Interventions in Persons With Mild Cognitive Impairment (clinicaltrials.gov) - Aug 8, 2012
P=N/A, N=162, Recruiting, Sponsor: Centre de Recherche de l'Institut Universitaire de Geriatrie de Montreal
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting

||||||||||  EVP-0962 / Forum Pharmaceuticals
New P2 trial:  Safety, Tolerability, Pharmacokinetics of EVP-0962 and Effects of EVP-0962 on Cerebral Spinal Fluid Amyloid Concentrations in Healthy Subjects and in Subjects With Mild Cognitive Impairment or Early Alzheimer's Disease (clinicaltrials.gov) -  Aug 7, 2012
P2, N=52, Completed,  Sponsor: EnVivo Pharmaceuticals, Inc.

|||||||||| Clinical: Enhanced External Counterpulsation and Its Effects on Vascular Hemodynamics in Cognitively Impaired Patients (clinicaltrials.gov) - Aug 5, 2012
P=N/A, N=10, Recruiting, Sponsor: Patrick Moriarty, MD, FACP, FACC

||||||||||  citalopram / Generic mfg., venlafaxine / Generic mfg., donepezil / Generic mfg.
New P4 trial:  DEP-CI: Combination Treatment Study for Memory Impairment and Depression (clinicaltrials.gov) -  Aug 2, 2012
P4, N=80, Recruiting,  Sponsor: New York State Psychiatric Institute

|||||||||| Clinical: A Trial of Neurocognitive and Supportive Therapy Interventions for Individuals With Parkinson's Disease (clinicaltrials.gov) - Jul 18, 2012
P=N/A, N=30, Recruiting, Sponsor: Virginia Commonwealth University

|||||||||| Trial completion: Performance of AclarusDx (clinicaltrials.gov) - Jul 3, 2012
P=N/A, N=160, Completed, Sponsor: Exonhit
Not yet recruiting --> Recruiting Recruiting --> Completed

||||||||||  thyroxine / Generic mfg.
Trial completion:  Subclinical Hypothyroidism and Mind in the Elderly (clinicaltrials.gov) -  Jun 26, 2012
P2/3, N=70, Completed,  Sponsor: Universidad Autonoma de Nuevo Leon
Recruiting --> Completed Active, not recruiting --> Completed

|||||||||| New P1 trial: U-SMART: Ubiquitous Spaced Retrieval-based Memory Advancement and Rehabilitation Training (clinicaltrials.gov) - Jun 25, 2012
P1, N=10, Completed, Sponsor: Seoul National University Bundang Hospital

|||||||||| Enrollment change: HIP: Hormone and Information Processing Study (clinicaltrials.gov) - Jun 14, 2012
P3, N=23, Completed, Sponsor: University of Washington
Active, not recruiting --> Completed N=12 --> 23

|||||||||| Trial completion: HIP: Hormone and Information Processing Study (clinicaltrials.gov) - Jun 14, 2012
P3, N=23, Completed, Sponsor: University of Washington
N=12 --> 23 Recruiting --> Completed

|||||||||| Trial termination: [18F]MK-3328 as a Possible Novel Positron Emission Tomography (PET) Tracer for the Detection of Brain Amyloid Plaques (MK-3328-002) (clinicaltrials.gov) - Jun 6, 2012
P1, N=20, Terminated, Sponsor: Merck Sharp & Dohme Corp.
Recruiting --> Completed Active, not recruiting --> Terminated

|||||||||| Trial termination: Early Intervention in Mild Cognitive Impairment (MCI) With Curcumin + Bioperine (clinicaltrials.gov) - May 24, 2012
P=N/A, N=10, Terminated, Sponsor: Louisiana State University Health Sciences Center Shreveport
Active, not recruiting --> Terminated Completed --> Terminated; For various reasons.

|||||||||| Clinical: Mindfulness Based Stress Reduction for Adults With Mild Cognitive Impairment (clinicaltrials.gov) - May 22, 2012
P=N/A, N=14, Completed, Sponsor: Beth Israel Deaconess Medical Center

||||||||||  itanapraced (CHF-5074) / CereSpir
New P2 trial:  CT04 POLEP: Evaluation of Safety & Tolerability of Multiple Dose Regimens of CHF 5074 and Exploration of Effects on Potential Markers of Clinical Efficacy in Patients With Mild Cognitive Impairment - Prolonged Open Label Extension Phase (clinicaltrials.gov) -  May 17, 2012
P2, N=51, Completed,  Sponsor: Chiesi Pharmaceuticals Inc.

||||||||||  GSK 933776 / GSK
Enrollment change:  Modulation of Abeta Levels by GSK933776 in Alzheimer's Disease Patient (clinicaltrials.gov) -  May 16, 2012
P1, N=19, Completed,  Sponsor: GlaxoSmithKline
Completed --> Terminated; For various reasons. N=35 --> 19

||||||||||  GSK 933776 / GSK
Trial completion:  Modulation of Abeta Levels by GSK933776 in Alzheimer's Disease Patient (clinicaltrials.gov) -  May 16, 2012
P1, N=19, Completed,  Sponsor: GlaxoSmithKline
N=35 --> 19 Active, not recruiting --> Completed

||||||||||  itanapraced (CHF-5074) / CereSpir
Trial completion:  Evaluation of Safety & Tolerability of Multiple Dose Regimens of CHF 5074 (clinicaltrials.gov) -  May 16, 2012
P2, N=96, Completed,  Sponsor: Chiesi Pharmaceuticals Inc.
Active, not recruiting --> Completed Active, not recruiting --> Completed

|||||||||| Clinical: Effects of Antimuscarinics on Cognition in Spinal Cord Injury (clinicaltrials.gov) - May 15, 2012
P=N/A, N=40, Recruiting, Sponsor: Swiss Paraplegic Centre Nottwil

|||||||||| New P2 trial: NMDA-enhancing Agent for Treatment of Mild Cognitive Impairment and Mild Alzheimer's Disease (clinicaltrials.gov) - May 15, 2012
P2, N=86, Completed, Sponsor: Chang Gung Memorial Hospital

||||||||||  elenbecestat (E2609) / Eisai, Biogen
New P1 trial:  Evaluation of E2609 in Subjects With Mild Cognitive Impairment or Mild Dementia Due to Alzheimer's Disease (Study: E2609-A001-101 Amendment 02) (clinicaltrials.gov) -  May 15, 2012
P1, N=65, Completed,  Sponsor: Eisai Inc.

|||||||||| Enrollment change, MRI: AMIMAGE: Evaluation of Alteration by Magnetic Resonance Imaging (MRI) in Dementia Among Elderly Subjects (clinicaltrials.gov) - Apr 26, 2012
P=N/A, N=318, Completed, Sponsor: University Hospital, Bordeaux
Active, not recruiting --> Completed N=400 --> 318

|||||||||| Enrollment change: A Clinical Trial of a Vitamin/Nutriceutical Formulation for Alzheimer's Disease (clinicaltrials.gov) - Apr 22, 2012
P2, N=135, Completed, Sponsor: University of Massachusetts, Worcester
N=400 --> 318 N=300 --> 135

|||||||||| Trial completion: A Clinical Trial of a Vitamin/Nutriceutical Formulation for Alzheimer's Disease (clinicaltrials.gov) - Apr 22, 2012
P2, N=135, Completed, Sponsor: University of Massachusetts, Worcester
N=300 --> 135 Recruiting --> Completed

||||||||||  galantamine hydrobromide / Generic mfg.
Enrollment change:  An Observational Study for Analysis of Mortality in Participants Who Participated in Previous 3 Studies of Galantamine (clinicaltrials.gov) -  Apr 10, 2012
P3, N=1083, Completed,  Sponsor: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Recruiting --> Completed N=2058 --> 1083

|||||||||| New P1 trial: Impact of Grape Consumption on Brain Metabolism and Cognitive Function (clinicaltrials.gov) - Apr 4, 2012
P1, N=12, Recruiting, Sponsor: University of California, Los Angeles

|||||||||| Trial completion: Prospective Research in Memory Clinics (PRIME) (clinicaltrials.gov) - Apr 2, 2012
P4, N=970, Completed, Sponsor: Janssen-Cilag Pty Ltd
N=2058 --> 1083 Active, not recruiting --> Completed

||||||||||  LY2886721 / Eli Lilly
New P1/2 trial:  Study of LY2886721 in Mild Cognitive Impairment Due to Alzheimer's Disease or Mild Alzheimer's Disease (clinicaltrials.gov) -  Mar 21, 2012
P1/2, N=128, Terminated,  Sponsor: Eli Lilly and Company

|||||||||| Enrollment open: Mild Cognitive Impairment and Obstructive Sleep Apnea (clinicaltrials.gov) - Mar 7, 2012
P3, N=110, Recruiting, Sponsor: George Mason University
Active, not recruiting --> Completed Not yet recruiting --> Recruiting

||||||||||  AZD-5213 / AstraZeneca
New P2a trial:  A Study of the Safety and Tolerability of AZD5213 Effect on Sleep for Patients With Alzheimer's/Cognitive Impairment (clinicaltrials.gov) -  Mar 6, 2012
P2a, N=81, Completed,  Sponsor: AstraZeneca

||||||||||  TTP4000 / vTv Therapeutics
New P1 trial:  A Safety Study of TTP4000 in Subjects With Alzheimer's Disease (clinicaltrials.gov) -  Mar 6, 2012
P1, N=16, Active, not recruiting,  Sponsor: TransTech Pharma

|||||||||| Enrollment change: Observational Study of Cognitive Outcomes for Subjects Who Have Had Prior PET Amyloid Imaging With Florbetapir F 18 (18F-AV-45) (clinicaltrials.gov) - Mar 5, 2012
P2, N=152, Completed, Sponsor: Avid Radiopharmaceuticals
Not yet recruiting --> Recruiting N=100 --> 152

||||||||||  Levemir (insulin detemir rDNA origin) / Novo Nordisk
New P2 trial:  Study of Nasal Insulin to Fight Forgetfulness - Long-acting Insulin Detemir - 21 Days (clinicaltrials.gov) -  Mar 5, 2012
P2, N=60, Completed,  Sponsor: University of Washington

|||||||||| Trial completion: Observational Study of Cognitive Outcomes for Subjects Who Have Had Prior PET Amyloid Imaging With Florbetapir F 18 (18F-AV-45) (clinicaltrials.gov) - Mar 5, 2012
P2, N=152, Completed, Sponsor: Avid Radiopharmaceuticals
N=100 --> 152 Active, not recruiting --> Completed

|||||||||| Biomarker, Trial completion, IO biomarker: Study of the Effects of Cerefolin NAC on Inflammation Blood Markers in Older Individuals With Memory Complaints (clinicaltrials.gov) - Feb 16, 2012
P=N/A, N=104, Completed, Sponsor: Rush University Medical Center
Active, not recruiting --> Completed Active, not recruiting --> Completed

|||||||||| Trial termination: MemoryXL Effects on Mild Cognitive Impairment Patients (clinicaltrials.gov) - Jan 24, 2012
P2, N=10, Terminated, Sponsor: University of Oklahoma
Active, not recruiting --> Completed Completed --> Terminated; Risk/benefit ratio did not indicate further study would be useful, or fair to future subjects.

||||||||||  rivastigmine transdermal / Generic mfg.
New P4 trial:  Mild Cognitive Impairment in Parkinson's Disease (clinicaltrials.gov) -  Jan 24, 2012
P4, N=28, Recruiting,  Sponsor: University of Pennsylvania